Cargando…

Expression of galectin-3 in gastric adenocarcinoma

BACKGROUND & OBJECTIVES: Galectin-3 a member of the galectin family is an endogenous β-galactoside binding lectin. It has been found to be associated with cell adhesion, recognition, proliferation, differentiation, immunomodulation, angiogenesis, apoptosis and can be a reliable marker for cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomes, Thiago Simão, Oshima, Celina Tizuko Fujiyama, Forones, Nora Manoukian, De Oliveira Lima, Flávio, Ribeiro, Daniel Araki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181163/
https://www.ncbi.nlm.nih.gov/pubmed/25222780
_version_ 1782337332123271168
author Gomes, Thiago Simão
Oshima, Celina Tizuko Fujiyama
Forones, Nora Manoukian
De Oliveira Lima, Flávio
Ribeiro, Daniel Araki
author_facet Gomes, Thiago Simão
Oshima, Celina Tizuko Fujiyama
Forones, Nora Manoukian
De Oliveira Lima, Flávio
Ribeiro, Daniel Araki
author_sort Gomes, Thiago Simão
collection PubMed
description BACKGROUND & OBJECTIVES: Galectin-3 a member of the galectin family is an endogenous β-galactoside binding lectin. It has been found to be associated with cell adhesion, recognition, proliferation, differentiation, immunomodulation, angiogenesis, apoptosis and can be a reliable marker for cancer aggressiveness. The aim of this study was to verify protein expression in gastric adenocarcinoma tissues and correlate the results with the clinical aspects in the study population. METHODS: Galectin-3 expression was examined by immunohistochemistry in 57 samples of gastric adenocarcinomas tissues. Galectin-3 protein expression was observed in the cytoplasm and the nucleus of examined tissues. RESULTS: Thirty one (54.4%) samples had strong or moderate staining and 26 (45.6%) tumours had negative or weak staining. The galectin-3 did not show association with the sex (P=0.347), age (P=0.999), Lauren's classification (P=0.731) and TNM stage (P=0.222). Regarding the TNM stage, 66.7 per cent of stage I tumours had strong or moderate staining; with tumours stage IV this percentage was 33.3 per cent. INTERPRETATION & CONCLUSION: Our results suggest that gal-3 is not a reliable biomarker for prognosis of the gastric adenocarcinoma by immunohistochemistry. Further studies need to be done on a large sample of tumour tissues in different clinical staging.
format Online
Article
Text
id pubmed-4181163
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-41811632014-10-14 Expression of galectin-3 in gastric adenocarcinoma Gomes, Thiago Simão Oshima, Celina Tizuko Fujiyama Forones, Nora Manoukian De Oliveira Lima, Flávio Ribeiro, Daniel Araki Indian J Med Res Original Article BACKGROUND & OBJECTIVES: Galectin-3 a member of the galectin family is an endogenous β-galactoside binding lectin. It has been found to be associated with cell adhesion, recognition, proliferation, differentiation, immunomodulation, angiogenesis, apoptosis and can be a reliable marker for cancer aggressiveness. The aim of this study was to verify protein expression in gastric adenocarcinoma tissues and correlate the results with the clinical aspects in the study population. METHODS: Galectin-3 expression was examined by immunohistochemistry in 57 samples of gastric adenocarcinomas tissues. Galectin-3 protein expression was observed in the cytoplasm and the nucleus of examined tissues. RESULTS: Thirty one (54.4%) samples had strong or moderate staining and 26 (45.6%) tumours had negative or weak staining. The galectin-3 did not show association with the sex (P=0.347), age (P=0.999), Lauren's classification (P=0.731) and TNM stage (P=0.222). Regarding the TNM stage, 66.7 per cent of stage I tumours had strong or moderate staining; with tumours stage IV this percentage was 33.3 per cent. INTERPRETATION & CONCLUSION: Our results suggest that gal-3 is not a reliable biomarker for prognosis of the gastric adenocarcinoma by immunohistochemistry. Further studies need to be done on a large sample of tumour tissues in different clinical staging. Medknow Publications & Media Pvt Ltd 2014-07 /pmc/articles/PMC4181163/ /pubmed/25222780 Text en Copyright: © Indian Journal of Medical Research http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Gomes, Thiago Simão
Oshima, Celina Tizuko Fujiyama
Forones, Nora Manoukian
De Oliveira Lima, Flávio
Ribeiro, Daniel Araki
Expression of galectin-3 in gastric adenocarcinoma
title Expression of galectin-3 in gastric adenocarcinoma
title_full Expression of galectin-3 in gastric adenocarcinoma
title_fullStr Expression of galectin-3 in gastric adenocarcinoma
title_full_unstemmed Expression of galectin-3 in gastric adenocarcinoma
title_short Expression of galectin-3 in gastric adenocarcinoma
title_sort expression of galectin-3 in gastric adenocarcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181163/
https://www.ncbi.nlm.nih.gov/pubmed/25222780
work_keys_str_mv AT gomesthiagosimao expressionofgalectin3ingastricadenocarcinoma
AT oshimacelinatizukofujiyama expressionofgalectin3ingastricadenocarcinoma
AT foronesnoramanoukian expressionofgalectin3ingastricadenocarcinoma
AT deoliveiralimaflavio expressionofgalectin3ingastricadenocarcinoma
AT ribeirodanielaraki expressionofgalectin3ingastricadenocarcinoma